% Expired Patents = 12.5

CIPO Patents = 3

EPO Patents = 2

Forward Citations = 30

Loading Chart...

8 inventors (with patents filed for the assignee):

Matthew Charles (3 out of 3 patents)

Mark F Williams (3 out of 57 patents)

Tadeusz Kolodka (2 out of 2 patents)

4. Todd Verdoorn (2 out of 4 patents)

5. Rick Pauls (2 out of 2 patents)

6. Wilfred Wayne Lautt (1 out of 4 patents)

7. W Wayne Lautt (1 out of 3 patents)

8. Paula Macedo (1 out of 1 patent)

9. Wayne W Lautt (0 patent)

8 patents: Sort by Forward Citations

1. 12329805 - Dosage forms of tissue kallikrein 1 (2025-06-17),

2. 11857608 - Dosage forms of tissue kallikrein 1 (2024-01-02),

3. 9839678 - Human tissue kallikrein 1 glycosylation isoforms (2017-12-12),

4. 9616015 - Formulations of human tissue kallikrein-1 for parenteral delivery and related methods (2017-04-11),

5. 9364521 - Human tissue kallikrein 1 glycosylation isoforms (2016-06-14),

6. 8673964 - Use of drug combinations for treating insulin resistance (2014-03-18),

7. 8501695 - Tissue kallikrein for the treatment of diseases associated with amyloid protein (2013-08-06),

8. 7622447 - Use of glutathione synthesis stimulating compounds in reducing insulin resistance (2009-11-24),

Diamedica is a medical technology company focused on developing innovative solutions for respiratory care. With a strong emphasis on research and development, Diamedica aims to improve patient outcomes and quality of life through cutting-edge products and technologies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

8 Patents

#23 in Winnipeg

#1,874 in Canada

Winnipeg, Canada

Diamedica Inc.

Forward Citations = 30

8 inventors:

Matthew Charles (3 out of 3 patents)

Mark F Williams (3 out of 57 patents)

Tadeusz Kolodka (2 out of 2 patents)

4. Todd Verdoorn (2 out of 4 patents)

5. Rick Pauls (2 out of 2 patents)

Please report any incorrect information to [email protected]

3 patents (CIPO):

Please report any incorrect information to [email protected]

2 patents (EPO):

Please report any incorrect information to [email protected]